SCHEDULE: Vivo Funds Disclose 8.4% Stake in Camp4 Therapeutics

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. have disclosed beneficial ownership of 8.4% of Camp4 Therapeutics Corp's common stock following a private placement.

Summary

• Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, beneficially own 3,561,793 shares of Camp4 Therapeutics Corp common stock, representing 7.6% of the class.
• Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, beneficially own 359,775 shares of Camp4 Therapeutics Corp common stock, representing 0.8% of the class.
• The total beneficial ownership by the Vivo entities is 3,921,568 shares, representing approximately 8.4% of the common stock.
• The percentage of class is calculated based on 46,878,487 shares of common stock, which includes 20,161,073 shares outstanding as of August 5, 2025, and 26,717,414 shares sold in a private placement transaction closed on September 11, 2025.
• The securities were not acquired for the purpose of changing or influencing control of Camp4 Therapeutics Corp.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake (8.4%) by Vivo funds, particularly following a private placement, generally signals investor confidence and provides capital to the company. The certification that the stake is not for control purposes suggests a passive, supportive investment.

Positives

• Significant investment by institutional funds (Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P.) indicates confidence in Camp4 Therapeutics Corp.
• The investment is part of a recent private placement, suggesting new capital infusion for the company.

Risks

• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Camp4 Therapeutics Corp, as it is a disclosure of beneficial ownership by an investor group.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant institutional investment in Camp4 Therapeutics Corp, a biotechnology company. Such filings are common after private placements or open market purchases where an entity crosses the 5% beneficial ownership threshold. For a biotech company, attracting institutional investment, especially through a private placement, can be a positive signal of investor confidence in its pipeline and strategic direction, providing capital for research and development in a capital-intensive industry.

Stakeholder Impact

• Shareholders: The entry of significant institutional investors can be viewed positively, potentially stabilizing the stock and providing a vote of confidence. The private placement itself would have diluted existing shareholders, but also provided capital.
• Company Management: The capital raise provides resources for operations and strategic initiatives. The passive nature of the investment (not for control) suggests alignment with current management.

Key Dates

Recommendation

The filing indicates a significant institutional investment in Camp4 Therapeutics Corp, which is generally a positive signal of confidence and provides capital. However, as a Schedule 13G, it primarily discloses ownership and does not offer detailed financial performance or strategic updates from the company itself. While the investment is a positive indicator, a 'hold' recommendation is appropriate without further information on the company's operational performance, pipeline progress, or valuation metrics. Investors should consider this alongside other company-specific and industry-wide data.

Keywords

Camp4 Therapeutics, Vivo Opportunity Fund, Vivo Opportunity Cayman, Beneficial Ownership, Schedule 13G, Common Stock, Private Placement, Institutional Investment, Biotechnology, Pharmaceuticals